Fibrostenosis Focused Therapeutics - RFP
The Crohn's and Colitis Foundation's Fibrostenosis Focused Therapeutics RFP funds research into novel, non-surgical therapies targeting fibrotic complications in IBD, especially fibrostenosis.
Funder: Crohn's and Colitis Foundation
Due Dates: May 31, 2026 (Preproposal) | June 30, 2026 (Letter of Intent) | August 14, 2026 (Full proposal)
Funding Amounts: Up to $450,000 per project for one year; renewals possible if milestones are met.
Summary: Supports development of innovative, non-surgical therapeutics targeting fibrotic complications in IBD, especially fibrostenosis.
Key Information: Preproposal submission is required before full proposal; both companies and academic groups with commercialization focus are eligible.
Description
This funding opportunity from the Crohn's and Colitis Foundation supports the development of novel, non-surgical therapeutics for fibrotic complications in inflammatory bowel disease (IBD), with a focus on fibrostenosis in Crohn's disease and ulcerative colitis. The program seeks proposals from both companies and academic groups (with demonstrated commercialization resources) to advance product-oriented research grounded in clinical observations or human IBD evidence. Projects should address unmet clinical needs by targeting fibrotic pathways or employing multidisciplinary approaches to therapeutic development. The initiative is milestone-driven, emphasizing translational research with a clear path toward commercialization and patient impact.
